 |
|
Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Osteoarthritis of the Knee
A Randomized Trial
Gregory P. Geba, MD;
Arthur L. Weaver, MD;
Adam B. Polis, MA;
Mary E. Dixon, BS;
Thomas J. Schnitzer, MD,PhD;
for the VACT Group
JAMA. 2002;287:64-71.
Context Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2).
Objective To assess the relative therapeutic efficacy of rofecoxib, celecoxib, and acetaminophen in adults with OA.
Design and Setting Randomized, parallel-group, double-blind trial, conducted from June 1999 to February 2000, in 29 clinical centers in the United States.
Patients Three hundred eighty-two patients aged at least 40 years who had OA of the knee that was previously treated with NSAIDs or acetaminophen.
Interventions Patients were randomly assigned to receive rofecoxib, 12.5 mg/d (n = 96); rofecoxib, 25 mg/d (n = 95); celecoxib, 200 mg/d (n = 97); or acetaminophen, 4000 mg/d (n = 94) for 6 weeks.
Main Outcome Measures Assessments over days 1 to 6 and over 6 weeks included pain on walking, night pain, pain at rest, and morning stiffness as measured on a Western Ontario McMaster Universities Osteoarthritis Index (100-mm visual analog scale [VAS]) and global response to therapy compared among 4 treatment groups.
Results 79% of patients completed the study. More patients treated with acetaminophen discontinued early due to lack of efficacy than patients treated with COX-2 inhibitors (31% vs 18%-19%). Efficacy assessed in the first 6 days of therapy showed greatest response to rofecoxib, 25 mg/d, followed by rofecoxib, 12.5 mg/d, celecoxib, and acetaminophen, respectively, in terms of relief of pain on walking (-32.2, - 29.0, - 26.4, and -20.6 mm change on the VAS; P .04 for all others vs acetaminophen; P = .05 for 25-mg rofecoxib vs celecoxib), rest pain (-21.8, - 18.6, - 15.5, and - 12.5 mm; P.02 for either dose of rofecoxib vs acetaminophen and P = .02 for rofecoxib, 25 mg/d, vs celecoxib), night pain (-25.2, - 22.0, - 18.7, and - 18.8 mm; P = .04 for rofecoxib, 25 mg/d, vs both acetaminophen and celecoxib), and morning stiffness (-30.4, - 28.4, - 25.7, and - 20.9 mm; P.02 for either dose of rofecoxib vs acetaminophen). Over 6 weeks, rofecoxib, 25 mg/d, provided greatest response for night pain (P<.002 vs celecoxib and P = .006 vs acetaminophen and P = .02 vs rofecoxib, 12.5 mg/d), composite pain subscale (P.03 vs all other treatments), stiffness subscale (P.04 vs celecoxib and acetaminophen), and physical function subscale (P = .001 vs acetaminophen). Global responses over 6 weeks showed a similar pattern (good or excellent response at week 6: 60%, 56%, 46%, and 39%, respectively; P.03 for rofecoxib, 25 mg/d, vs celecoxib and acetaminophen; P = .02 for rofecoxib, 12.5 mg/d, vs acetaminophen). All treatments were generally safe and well tolerated.
Conclusion Rofecoxib, 25 mg/d, provided efficacy advantages over acetaminophen, 4000 mg/d, celecoxib, 200 mg/d, and rofecoxib, 12.5 mg, for symptomatic knee OA.
Author Affiliations: Merck & Co Inc, West Point, Pa (Dr Geba, Mr Polis, and Ms Dixon); Arthritis Center of Nebraska, Lincoln (Dr Weaver); and Northwestern University, Chicago, Ill (Dr Schnitzer).
RELATED LETTER
Rofecoxib vs Celecoxib vs Acetaminophen for Treatment of Osteoarthritis
S. M. A. Bierma-Zeinstra, A. M. Bohnen, M. Y. Berger, S. Thomas, Philip Henderson, Gregory P. Geba, Adam B. Polis, Arthur L. Weaver, and Thomas J. Schnitzer
JAMA. 2002;287(14):1799-1800.
EXTRACT
| FULL TEXT
RELATED ARTICLE
January 2, 2002
JAMA. 2002;287(1):129-130.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Ross et al.
JAMA 2008;299:1800-1812.
ABSTRACT
| FULL TEXT
Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence
DeAngelis and Fontanarosa
JAMA 2008;299:1833-1835.
FULL TEXT
An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong et al.
Clin Med Res 2007;5:19-34.
ABSTRACT
| FULL TEXT
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
Bingham et al.
Rheumatology (Oxford) 2007;46:496-507.
ABSTRACT
| FULL TEXT
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors
Yazici and Yazici
Ann Rheum Dis 2007;66:124-127.
ABSTRACT
| FULL TEXT
Massage Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial
Perlman et al.
Arch Intern Med 2006;166:2533-2538.
ABSTRACT
| FULL TEXT
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials
Zhang et al.
JAMA 2006;296:1619-1632.
ABSTRACT
| FULL TEXT
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.
Watkins et al.
JAMA 2006;296:87-93.
ABSTRACT
| FULL TEXT
Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis
Mastbergen et al.
Rheumatology (Oxford) 2006;45:405-413.
ABSTRACT
| FULL TEXT
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
Caldwell et al.
JRSM 2006;99:132-140.
ABSTRACT
| FULL TEXT
Blood-nourishing and Hard-softening Capsule Costs Less in the Management of Osteoarthritic Knee Pain: A Randomized Controlled Trial
Cao et al.
Evid Based Complement Alternat Med 2005;2:363-368.
ABSTRACT
| FULL TEXT
The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus
Sowers et al.
Arch Intern Med 2005;165:161-168.
ABSTRACT
| FULL TEXT
A historic issue of the Annals: three papers examine paracetamol in osteoarthritis
Neame et al.
Ann Rheum Dis 2004;63:897-900.
FULL TEXT
Paracetamol in osteoarthritis of the knee
Miceli-Richard et al.
Ann Rheum Dis 2004;63:923-930.
ABSTRACT
| FULL TEXT
Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials
Zhang et al.
Ann Rheum Dis 2004;63:901-907.
ABSTRACT
| FULL TEXT
Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis
Pincus et al.
Ann Rheum Dis 2004;63:931-939.
ABSTRACT
| FULL TEXT
Pharmacologic Management of Foot Pain in the Older Patient
Martin
J. Am. Podiatr. Med. Assoc. 2004;94:98-103.
ABSTRACT
| FULL TEXT
Cyclooxygenases, the Kidney, and Hypertension
Cheng and Harris
Hypertension 2004;43:525-530.
ABSTRACT
| FULL TEXT
Non-surgical treatment of osteoarthritis: a half century of "advances"
Brandt
Ann Rheum Dis 2004;63:117-122.
FULL TEXT
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
Jordan et al.
Ann Rheum Dis 2003;62:1145-1155.
ABSTRACT
| FULL TEXT
Cyclooxygenase-2 Inhibitors
Gajraj
Anesth. Analg. 2003;96:1720-1738.
FULL TEXT
The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis
Spiegel et al.
ANN INTERN MED 2003;138:795-806.
ABSTRACT
| FULL TEXT
Effect of Cyclooxygenase-2 Inhibitors on Blood Pressure
Johnson et al.
The Annals of Pharmacotherapy 2003;37:442-446.
ABSTRACT
| FULL TEXT
Opposite Effects of Rofecoxib on Nuclear Factor-kappa B and Activating Protein-1 Activation
Niederberger et al.
J. Pharmacol. Exp. Ther. 2003;304:1153-1160.
ABSTRACT
| FULL TEXT
Lack of Efficacy of Acetaminophen in Treating Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo-Controlled Comparison Trial With Diclofenac Sodium
Case et al.
Arch Intern Med 2003;163:169-178.
ABSTRACT
| FULL TEXT
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT
Key questions concerning paracetamol and NSAIDs for osteoarthritis
Courtney and Doherty
Ann Rheum Dis 2002;61:767-773.
FULL TEXT
Rofecoxib, 25 mg/day, was more effective than rofecoxib, 12.5 mg/day, celecoxib, or acetaminophen in osteoarthritis of the knee
Meyerhoff
Evid. Based Med. 2002;7:123-123.
FULL TEXT
Potential alternatives to COX 2 inhibitors
Skelly and Hawkey
BMJ 2002;324:1289-1290.
FULL TEXT
Rofecoxib vs Celecoxib vs Acetaminophen for Treatment of Osteoarthritis
Bierma-Zeinstra et al.
JAMA 2002;287:1799-1800.
FULL TEXT
COX-2 NSAIDs Superior to Acetaminophen for Knee Osteoarthritis
JWatch Emergency Med. 2002;2002:7-7.
FULL TEXT
Selective COX-2 Inhibitors vs. Acetaminophen for Knee Osteoarthritis
JWatch General 2002;2002:2-2.
FULL TEXT
|
